AstraZeneca PLC (AZN)vs908 Devices Inc (MASS)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
MASS
908 Devices Inc
$6.83
+5.08%
HEALTHCARE · Cap: $251.94M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 104423% more annual revenue ($58.74B vs $56.20M). MASS leads profitability with a 34.7% profit margin vs 17.4%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
MASS
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
+57.9%
Fair Value
$15.66
Current Price
$6.83
$8.83 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Keeps 35 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -25.8% — below average capital efficiency
Revenue declined 7.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : MASS
The strongest argument for MASS centers on Profit Margin, Debt/Equity, Price/Book. Profitability is solid with margins at 34.7% and operating margin at -17.3%.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : MASS
The primary concerns for MASS are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a value stock while MASS is a declining play — different risk/reward profiles.
MASS carries more volatility with a beta of 0.53 — expect wider price swings.
AZN is growing revenue faster at 4.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 37/100), backed by strong 17.4% margins. MASS offers better value entry with a 57.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
908 Devices Inc
HEALTHCARE · MEDICAL DEVICES · USA
908 Devices Inc. develops and sells measuring devices for chemical and biochemical analysis in North America, Europe, the Middle East, Africa, and Asia Pacific. The company is headquartered in Boston, Massachusetts.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?